Study of KHN939 for thyroid eye disease
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new medication, KHN939, for people with moderate-to-severe active thyroid eye disease. It aims to reduce eye bulging and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You weigh between 99 and 220 pounds (45 to 100 kg).
- You have been diagnosed with moderate-to-severe active thyroid eye disease, with symptoms starting less than 12 months ago.
- You have not already been treated with certain medications for this condition (your doctor will check this).
- Women who can become pregnant must have a negative pregnancy test and use birth control; men must also use birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, KHN939, for people with moderate-to-severe thyroid eye disease that is no longer active. It aims to see if the drug can improve symptoms like bulging eyes, eyelid retraction, or double vision.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
This trial tests a new drug called NTB003 for people with moderate-to-severe thyroid eye disease (TED). It aims to see if the drug can improve symptoms like eye bulging and double vision, and it may be an option for those whose disease is active or has been ongoing for a while.
This early-stage trial tests a new drug called IBI3031 to treat active thyroid eye disease (TED), a condition where the immune system attacks muscles and tissue around the eyes, causing swelling, bulging, and sometimes double vision. The study aims to see if this drug can reduce inflammation and improve symptoms.
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
This trial tests a new medicine called MHB018A for people with active, moderate to severe thyroid eye disease. It aims to see if the drug can reduce eye symptoms like bulging and inflammation.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.